Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia (original) (raw)

• McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708–722.
  Article CAS Google Scholar
• Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S et al. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010; 24: 1686–1699.
  Article CAS Google Scholar
• Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22: 686–707.
  Article CAS Google Scholar
• Vu C, Fruman DA . Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res 2010; 16: 5374–5380.
  Article CAS Google Scholar
• Zoncu R, Efeyan A, Sabatini DM . mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21–35.
  Article CAS Google Scholar
• Thoreen CC, Sabatini DM . Rapamycin inhibits mTORC1, but not completely. Autophagy 2009; 5: 725–726.
  Article CAS Google Scholar
• Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011; 17: 4378–4388.
  Article CAS Google Scholar
• Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010; 107: 12469–12474.
  Article CAS Google Scholar
• Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205–213.
  Article CAS Google Scholar
• Engelman JA, Luo J, Cantley LC . The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 619.
  Article Google Scholar
• Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008; 118: 3038–3050.
  Article CAS Google Scholar
• Garrett JT, Chakrabarty A, Arteaga CL . Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget 2011; 2: 1314–1321.
  Article Google Scholar
• Liu P, Cheng H, Roberts TM, Zhao JJ . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627–644.
  Article CAS Google Scholar
• Fan QW . A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341–349.
  Article CAS Google Scholar
• Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851–1863.
  Article CAS Google Scholar
• Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 2012; 23: 2399–2408.
  Article CAS Google Scholar
• Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 2011; 13: 384–392.
  Article CAS Google Scholar
• Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007; 67: 5840–5850.
  Article CAS Google Scholar
• Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022–8030.
  Article CAS Google Scholar
• Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10: 2426–2436.
  Article CAS Google Scholar
• Janes MR, Fruman DA . Targeting TOR dependence in cancer. Oncotarget 2010; 1: 69–76.
  PubMed PubMed Central Google Scholar
• Vilar E, Perez-Garcia J, Tabernero J . Pushing the envelope in the mTOR pathway. The second generation of inhibitors. Mol Cancer Ther 2011; 10: 395–403.
  Article CAS Google Scholar
• Wander SA, Hennessy BT, Slingerland JM . Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231–1241.
  Article CAS Google Scholar
• Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55–61.
  Article CAS Google Scholar
• Garcia-Garcia C, Ibrahim YH, Serra V, Calvo MT, Guzman M, Grueso J et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 2012; 18: 2603–2612.
  Article CAS Google Scholar
• Pui CH, Robison LL, Look AT . Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030–1043.
  Article CAS Google Scholar
• Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008; 4: 691–699.
  Article CAS Google Scholar
• Janes MR, Fruman DA . The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia. Methods Mol Biol 2012; 821: 251–265.
  Article CAS Google Scholar
• Jessen K, Wang S, Kessler L, Guo X, Kucharski J, Staunton J et al. INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity. Mol Cancer Ther 2009; 8: B148.
  Article Google Scholar
• Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010; 120: 1310–1323.
  Article CAS Google Scholar